Personalized cancer vaccine proves promising in a phase 1 trial

Researchers at the Icahn School of Medicine at Mount Sinai, led by Nina Bhardwaj, MD, Ph.D., Ward-Coleman Chair in Cancer Research and Director of the Vaccine and Cell Therapy Laboratory, have tested a promising new type of personalized multi-peptide neoantigen cancer vaccine, called PGV001, in a small group of patients.